WEBVTT
00:00.031 --> 00:17.099
[SPEAKER_00]: These probably are the mechanisms why stem cells can help autism cases, so it can help improve endogenesis, modulating immune system, can reduce apoptosis, so reduce cell damage, and to oxidant effect, modulate the excitation, response, and restore neuroconnectivity.
00:17.179 --> 00:19.823
[SPEAKER_00]: Welcome to the Dr. Duay Kong podcast.
00:19.843 --> 00:27.135
[SPEAKER_00]: This is where I have a chance to share with you some of the latest developments in the space of holistic health, longevity, and wellness.
00:27.115 --> 00:34.067
[SPEAKER_00]: I've always honored intellectual curiosity and scientific rigor, combined with real world practicality.
00:34.368 --> 00:38.776
[SPEAKER_00]: My goal is that what you learn here will help you live longer and live better.
00:39.076 --> 00:40.479
[SPEAKER_00]: Hope you enjoy the journey with me.
00:41.080 --> 00:45.327
[SPEAKER_00]: I think the purpose of this is really to talk about
00:46.083 --> 00:47.505
[SPEAKER_00]: What kind of evidence is there?
00:47.525 --> 00:57.442
[SPEAKER_00]: You know, we're all passionate about stem cell treatment, but what I've always been focusing on is what kind of evidence I can present to my patients.
00:58.243 --> 01:04.834
[SPEAKER_00]: And is actually pretty impressive how much evidence is out there.
01:04.814 --> 01:05.736
[SPEAKER_00]: have prepared.
01:05.756 --> 01:07.399
[SPEAKER_00]: It's going to be a lot of slide.
01:07.419 --> 01:08.901
[SPEAKER_00]: So I'm going to just be zooming through them.
01:09.562 --> 01:15.032
[SPEAKER_00]: But I just want to give you an idea of what's out there and what kind of conditions have been studied.
01:15.453 --> 01:24.308
[SPEAKER_00]: So you can take that back into your clinic and really, really help, you know, make some differences in places where maybe you, you didn't know that there's some evidence about.
01:24.288 --> 01:25.831
[SPEAKER_00]: stems off the treatments.
01:26.252 --> 01:30.320
[SPEAKER_00]: So yeah, so I found in American Academy of Integrated South Therapy.
01:30.981 --> 01:39.698
[SPEAKER_00]: I do we do have a clinical course called Fundamentals of stem cell practice where I go into more detail, but let's start.
01:39.678 --> 01:41.682
[SPEAKER_00]: So, first of all, autoimmune condition.
01:41.822 --> 01:48.034
[SPEAKER_00]: That's the one condition we know that one category we know that stem cell therapy has been powerful in.
01:48.655 --> 01:50.740
[SPEAKER_00]: And let's just take a look at first lupus.
01:51.140 --> 01:56.391
[SPEAKER_00]: So, this is using on local cord MICs in severe refractory lupus patients.
01:56.411 --> 01:57.653
[SPEAKER_00]: So, 16 patients.
01:57.633 --> 02:10.331
[SPEAKER_00]: There is significant decrease in disease severity and including improvement in markers and reduction in disease activity achieved in all these 60 patients with no recurrence three years later.
02:10.351 --> 02:12.133
[SPEAKER_00]: So that's pretty impressive.
02:12.574 --> 02:27.555
[SPEAKER_00]: And here's another study, 40 patients using on local court MICs in active and refractory loopous patients and they were able to see major clinical response
02:27.535 --> 02:32.662
[SPEAKER_00]: And on nine months, there are some railops rate and 12 months, you know, about 16% railops rate.
02:33.042 --> 02:38.650
[SPEAKER_00]: So their conclusion is that you likely require, require new infusion in about six months.
02:39.451 --> 02:40.512
[SPEAKER_00]: And rheumatoid arthritis.
02:40.932 --> 02:46.179
[SPEAKER_00]: So this is study again using a local core MSCs for people with active rheumatoid arthritis.
02:46.540 --> 02:49.003
[SPEAKER_00]: And there's significant remission
02:48.983 --> 03:06.874
[SPEAKER_00]: in all the MSC treatment groups, including improvement in their sleep, diet, physical strength to, you know, as soon as two weeks post treatment, and joints swelling were alleviated even within 12 hours and maintained throughout the study.
03:06.854 --> 03:08.638
[SPEAKER_00]: And here's inflammatory bowel disease.
03:09.560 --> 03:22.909
[SPEAKER_00]: Traditionally, we were using hematopuetic stem cells to treat patients, but that has various drawbacks, partially because you require chemotherapy and antibiotics and steroid.
03:22.929 --> 03:25.254
[SPEAKER_00]: It just, there are a lot of side effects.
03:25.975 --> 03:27.158
[SPEAKER_00]: And the new,
03:27.138 --> 03:47.078
[SPEAKER_00]: approach, probably a better approach is using mesenchymal stem cells, and you can do it locally or systemically, so here's an example of perinatal fistula, and local injections were able to help achieve 85.7% successful success rate in the healing of the fistula at 12 weeks.
03:47.839 --> 03:56.368
[SPEAKER_00]: And another example for Crohn's disease, using IV bone marrow derived stem cells, they were able to achieve
03:56.348 --> 04:03.258
[SPEAKER_00]: a end point that indicates remission in a 148 out of 207 patient.
04:03.298 --> 04:04.680
[SPEAKER_00]: So that's quite impressive.
04:05.642 --> 04:07.505
[SPEAKER_00]: For Crohn's disease, here's another study.
04:07.525 --> 04:13.814
[SPEAKER_00]: 82 patients, they were given IV infusions of the umbilical cord stem cells.
04:14.195 --> 04:21.225
[SPEAKER_00]: MSCs at 12 months, they show significant decrease in their symptoms and also decrease in the steroid dose.
04:22.218 --> 04:30.437
[SPEAKER_00]: So here's a visual picture of what you can see in the Mikoso layer and the improvement in the tissue.
04:30.878 --> 04:35.969
[SPEAKER_00]: School or a square or a Derma in refractures go to square or a Derma.
04:35.989 --> 04:39.096
[SPEAKER_00]: So this is only case study.
04:39.076 --> 04:54.141
[SPEAKER_00]: They were using a local core DMSC's and looking at actually patients achieving remission and they were able to sustain the results for 12 and 6 months.
04:54.682 --> 05:05.640
[SPEAKER_00]: And the second treatment, when they did it, they actually did not use any medications, any plasma for races, so they just gave stem cell straight and that still worked very well.
05:05.620 --> 05:07.062
[SPEAKER_00]: cardiovascular condition.
05:07.082 --> 05:09.205
[SPEAKER_00]: I'm going going to fast because there are a lot of conditions.
05:09.566 --> 05:24.287
[SPEAKER_00]: So athletes to growuses, these are so some studies mice were treated with MSCs and they were able to show reduction in the plaques and also inflammatory markers.
05:24.267 --> 05:31.628
[SPEAKER_00]: and they were able to reduce cholesterol and able to reduce the bascular lesion by 33% in the aortic root.
05:31.949 --> 05:36.803
[SPEAKER_00]: So here you can see a visual lesion size decrease and macrophage content decrease at the site.
05:37.525 --> 05:39.390
[SPEAKER_00]: Myocardial infarction.
05:39.370 --> 05:42.034
[SPEAKER_00]: human and local court blood transplanting.
05:43.076 --> 05:44.999
[SPEAKER_00]: So this is a first one is a mice study.
05:45.019 --> 05:52.091
[SPEAKER_00]: They showed reduced infarct volume with 20% higher capillary density around the infarct area.
05:52.131 --> 06:03.049
[SPEAKER_00]: So that shows, you know, recovery of the tissue, 2006 rat study and local court blood cells was able to colonize in the infarct area.
06:03.029 --> 06:21.173
[SPEAKER_00]: and what's fascinating, this is a rat, and they showed the cells around the blood vessels were actually of human origin, so they were actually settling down in a different species, and still was able to help, you know, help, you know,
06:21.878 --> 06:23.180
[SPEAKER_00]: the regeneration.
06:23.740 --> 06:36.117
[SPEAKER_00]: And the RAS study in 2009 also showed, you know, some correlation with higher veggie levels and the cells were able to concentrate in in farce area.
06:36.137 --> 06:43.887
[SPEAKER_00]: So their conclusion was IV infusion actually was a adequate strategy for treating the heart.
06:45.638 --> 06:46.739
[SPEAKER_00]: Okay, I'm sorry, I went back.
06:47.280 --> 06:48.641
[SPEAKER_00]: Okay, here's another study.
06:50.162 --> 06:57.990
[SPEAKER_00]: Looking at MSC's, how it helps the recovery in breaking down scar tissue after MI.
06:58.710 --> 07:07.699
[SPEAKER_00]: And two months after MSC treatment, the exchemic heart showed large improvement in left-end curricular anterior walled thickness in the infarct area.
07:08.420 --> 07:11.583
[SPEAKER_00]: And of course, the ejection fraction was improved.
07:12.043 --> 07:14.025
[SPEAKER_00]: And congested part failure,
07:14.005 --> 07:29.245
[SPEAKER_00]: Um, intravenous infusion of emblocal cord MSCs in heart failure patients were able to show that the treatment group was improved in left-on-tricular function and quality of life at three six and twelve months follow-up.
07:29.265 --> 07:34.512
[SPEAKER_00]: Um, so it decreased their hospitalization and decreased their arithmetic events.
07:34.492 --> 07:37.234
[SPEAKER_00]: And here's another congested heart failure.
07:38.075 --> 07:45.341
[SPEAKER_00]: Some more studies showing the allergenic cells actually increase Levantricular ejection fractions significantly.
07:45.862 --> 07:54.569
[SPEAKER_00]: And MSCs from either adipose or bone marrow do not increase the Levantricular ejection fraction compared to controls.
07:55.070 --> 08:04.498
[SPEAKER_00]: So in this case, the allergenic controlled a higher efficacy.
08:04.478 --> 08:11.326
[SPEAKER_00]: either around the heart, right around the heart, or intravenously, do not show that much difference in the improvement.
08:11.686 --> 08:12.727
[SPEAKER_00]: So that's really interesting.
08:12.747 --> 08:27.343
[SPEAKER_00]: And this is why I'm so excited, and you know, because such an elegant approach to give people an IV treatment because I do count on the natural intelligence of the cells to find the areas where they're needed and we can see more of the evidence as I go through other organ systems.
08:28.665 --> 08:29.145
[SPEAKER_00]: Diabetes.
08:29.746 --> 08:31.448
[SPEAKER_00]: So type one diabetes.
08:31.428 --> 08:48.188
[SPEAKER_00]: 29 patients, newly onset type 1 diabetes, they were given 2 infusions for weeks apart and they were able to show improvement in hemoglobin A1C and C peptide in these patients comparing to before the treatment or comparing to placebo group.
08:48.168 --> 08:57.269
[SPEAKER_00]: and another study using Wharton Jelly, MSC, and they were able to show that these MSC could, even though they're called methanchymal stem cells, right?
08:57.289 --> 09:05.046
[SPEAKER_00]: So they're supposed to be from Mesoderm layer, but they can cross this germ layer, you know, differences.
09:05.026 --> 09:08.590
[SPEAKER_00]: and differentiate into insulin-producing cells.
09:08.670 --> 09:10.532
[SPEAKER_00]: So that's pretty cool, pretty exciting.
09:11.714 --> 09:18.742
[SPEAKER_00]: So after MIC transplantation, what's fascinating is that some of these insulin-producing cells were located in the liver.
09:19.383 --> 09:24.288
[SPEAKER_00]: And still, even though they were in the liver, they were still able to normalize the hypergalicemia.
09:25.089 --> 09:34.240
[SPEAKER_00]: And warden's jelly MSEs can be differentiated better than bone marrow MSEs toward the mature beta cell type.
09:34.658 --> 09:35.879
[SPEAKER_00]: and type two diabetes.
09:36.500 --> 09:43.968
[SPEAKER_00]: So this is study showing 22 patients, given IV injection, plus intra-pancreatic injection.
09:44.508 --> 10:02.607
[SPEAKER_00]: And they were able to use the umbilical cord, I mean, what in jelly MSCs, they were able to significantly decrease the level of blood sugar and hemocopent A1C and improve CPAP-type levels, showing that nurse better beta-false cell function and reduce marker of systemic inflammation.
10:02.587 --> 10:13.860
[SPEAKER_00]: the hemoglobulin A1C level was lowest at three months post treatment, but the improvement was sustained at 12 months, so that shows the long-term benefit of these stem-salt treatments.
10:13.880 --> 10:19.886
[SPEAKER_00]: And here's another study, adult, allergenic, bone marrow-derived MSC's MSC precursor cells.
10:19.906 --> 10:21.809
[SPEAKER_00]: So this is something that's similar to MSC's.
10:22.970 --> 10:30.298
[SPEAKER_00]: They when compared with placebo's, these the patients who
10:30.278 --> 10:39.587
[SPEAKER_00]: or given the some cells were able to reduce hemoglobin A1C, so just more proof.
10:39.607 --> 10:40.868
[SPEAKER_00]: And then we come to neurological.
10:40.928 --> 10:56.944
[SPEAKER_00]: So a hemorrhage stroke, we can use intravenently transclanity, human and local core cells, which when they were given intravenously, they could migrate selectively to the area of the lesion.
10:57.633 --> 11:01.458
[SPEAKER_00]: and result in better functional tests performance in seven and 14 weeks.
11:01.518 --> 11:04.581
[SPEAKER_00]: So again, intravenous, the cells and intelligence would guide them there.
11:04.621 --> 11:12.311
[SPEAKER_00]: And for here's an exchemic stroke using autologous bone marrow MSCs.
11:12.991 --> 11:18.097
[SPEAKER_00]: And they were able to show functional recovery more frequently than control.
11:18.838 --> 11:26.948
[SPEAKER_00]: And the cumulative survival rate was much higher, so twice as high in the treatment group than the control group.
11:26.928 --> 11:30.072
[SPEAKER_00]: And spinal cord injury, we're talking about spinal cord injury.
11:30.092 --> 11:36.679
[SPEAKER_00]: So here's a study on a vocal cord derived stem cells, 25 patients.
11:36.739 --> 11:40.183
[SPEAKER_00]: They were given both intravenous and then later on intrathecal.
11:40.544 --> 11:45.309
[SPEAKER_00]: So I 12 months after treatment, there's some improvements.
11:45.449 --> 11:53.138
[SPEAKER_00]: So I wish it's higher, but I think in spinal cord injury cases, the expectation is more tempered.
11:53.118 --> 12:14.687
[SPEAKER_00]: which was why it's so exciting to see what they're doing in China, so here you can see 16% showed improvement in the American's final injury association score and spasm decrees in 28 percent of patients and then autumn non-function improve in 32 percent and there's some 24 percent had improved urinary function.
12:15.477 --> 12:20.884
[SPEAKER_00]: And in traumatic brain injury, MSCs do have the ability to cross the endothelial layer.
12:20.904 --> 12:22.265
[SPEAKER_00]: So cross the blood brain barrier.
12:22.285 --> 12:23.527
[SPEAKER_00]: So a lot of people don't know.
12:23.587 --> 12:27.992
[SPEAKER_00]: They think that MSCs, because their cells, their stem cells, they can't cross the blood brain barrier.
12:28.233 --> 12:36.303
[SPEAKER_00]: But no, MSCs actually have a particular capability to integrate into the endothelium and then cross the layer.
12:36.843 --> 12:42.430
[SPEAKER_00]: And so they were able to influence the tight junction barrier.
12:42.410 --> 12:45.273
[SPEAKER_00]: and they're able to decrease inflammation.
12:45.313 --> 12:48.677
[SPEAKER_00]: So this is an important property of MSEs.
12:49.498 --> 12:56.286
[SPEAKER_00]: So here's a lot of pre-clinical studies showing bone marrow and mononuclear cells improving TBI outcomes.
12:57.067 --> 13:08.100
[SPEAKER_00]: And in a phase one study of children with severe TBI, they were showing that there is not only safety, but also central nervous system, structural preservation type of effect.
13:08.620 --> 13:11.944
[SPEAKER_00]: Another study of 25 adults with severe TBI,
13:11.924 --> 13:25.885
[SPEAKER_00]: And this is within 36 hours injury, they were able to show that with stem salt treatment, there were structural preservation and critical regions that were correlated with functional outcome.
13:26.526 --> 13:32.174
[SPEAKER_00]: And they also were able to downregulate inflammatory biomarkers.
13:32.995 --> 13:38.083
[SPEAKER_00]: And when infused intravenously, these cells,
13:38.063 --> 13:49.318
[SPEAKER_00]: are able to have similar methods of action whether or not by dampening the innate immune system.
13:49.358 --> 13:57.709
[SPEAKER_00]: So I think we just need to keep in mind that the power of IV infusions because not only
13:57.689 --> 14:07.281
[SPEAKER_00]: It will travel to the site of injury, but it's also going to talk with your entire immune system and invoke the help of your spleen and your peripheral lymphoy system.
14:07.361 --> 14:11.546
[SPEAKER_00]: So I don't think we can underestimate the power of your entire body.
14:11.807 --> 14:26.565
[SPEAKER_00]: Instead of focusing on local injection, this is why I think even for central nervous systems is, you know, intranazzo is a great method, but I think it's important to still bring the power of your systemic of your entire body into place.
14:27.794 --> 14:39.279
[SPEAKER_00]: Another study, this is an animal study, MSC's can selectively migrate to injury-brain areas, and differentiate into neurons and aftersites.
14:39.299 --> 14:47.878
[SPEAKER_00]: So that's another thing that, you know, that even though their measled germ cells, right, messin' kymos times cells, but they can differentiate into neurotissue.
14:47.858 --> 15:05.580
[SPEAKER_00]: And another study showed that after MSC treatment, the different growth factors, the nerve growth factor, brain-dravener, neurotropic factor, were significantly increased during six-month follow-up and correlating with neurological function improvement.
15:05.560 --> 15:06.381
[SPEAKER_00]: and migraines.
15:06.742 --> 15:13.913
[SPEAKER_00]: So these are very severely ill patients, sometimes have daily or even twice daily migraines.
15:14.213 --> 15:16.296
[SPEAKER_00]: So this is a small study.
15:16.376 --> 15:17.138
[SPEAKER_00]: Only four women.
15:17.478 --> 15:23.367
[SPEAKER_00]: They were giving them IV, strumovascular fraction, and all experienced dramatic improvements.
15:23.347 --> 15:27.393
[SPEAKER_00]: some required repeat infusions seven to 18 months after.
15:28.114 --> 15:34.564
[SPEAKER_00]: And then another study had nine patients and they also show some benefit, but they were doing IAM injections.
15:35.405 --> 15:42.977
[SPEAKER_00]: So these did not produce as profound of the effect as studies using IV SVF.
15:42.997 --> 15:48.044
[SPEAKER_00]: So I think that probably speaks to the power of the intravenous method.
15:49.567 --> 15:51.109
[SPEAKER_00]: Orthopedic conditions.
15:51.342 --> 15:55.007
[SPEAKER_00]: Um, I love this study because it's so powerful.
15:55.392 --> 16:04.703
[SPEAKER_00]: So basically, 30 patients, they all has steroid induced osteo-necrosis.
16:04.723 --> 16:07.506
[SPEAKER_00]: So bones are going dead in both knees.
16:07.906 --> 16:11.430
[SPEAKER_00]: So they would need typically bilateral knee replacement.
16:11.851 --> 16:16.676
[SPEAKER_00]: But what they did was they divide the patient from the center line.
16:16.996 --> 16:19.479
[SPEAKER_00]: So they would do one knee replaced.
16:19.820 --> 16:23.644
[SPEAKER_00]: The other knee inject, I think bone marrow derived stem cells.
16:23.624 --> 16:24.766
[SPEAKER_00]: and look at the outcome.
16:24.786 --> 16:34.179
[SPEAKER_00]: So what happened was really fascinating is that at 12-year follow-up, six of the 30 total knee replacement patients actually needed a revision surgery.
16:34.560 --> 16:37.584
[SPEAKER_00]: So still, you know, six out of 30, that's one fifth.
16:38.005 --> 16:44.494
[SPEAKER_00]: But the knee that only got bone marrow derived stem cells, only one actually needed surgery at all.
16:44.755 --> 16:46.257
[SPEAKER_00]: So this is a very powerful study.
16:47.637 --> 16:48.899
[SPEAKER_00]: degenerative disc disease.
16:49.220 --> 16:55.249
[SPEAKER_00]: So some studies have shown that MSCs can restore disc height and function and improve symptoms.
16:55.269 --> 16:57.793
[SPEAKER_00]: Another study was looking at 10 patients.
16:57.933 --> 17:04.904
[SPEAKER_00]: Autologous expanded MSCs injected into the nucleus and showed rapid improvement in pain and disability.
17:05.826 --> 17:14.860
[SPEAKER_00]: And so a local cord MSCs, they actually could induce synthesis of proteoglycans and restore distructure.
17:15.785 --> 17:28.477
[SPEAKER_00]: A Vasculine Ecrosis, stem cells, so whether or not it's early disease or a later stage disease does have something to do with how patient and how well they do with stem cell treatment.
17:28.497 --> 17:44.813
[SPEAKER_00]: So it is early pre-collapse type disease in a Vasculine Ecrosis of the hip, you know, at the femoral head, only 9 out of 145 of those hips actually required total hip replacement.
17:44.793 --> 17:51.946
[SPEAKER_00]: you know, more than half act will end it up require total hip replacement and collizing sponolitis.
17:53.189 --> 18:02.807
[SPEAKER_00]: These are, of course, inflammatory disease and, you know, their suspicions that they actually have dysfunctional MSC.
18:02.827 --> 18:04.590
[SPEAKER_00]: So these patients have impaired.
18:04.570 --> 18:06.513
[SPEAKER_00]: in the regulatory capabilities.
18:07.193 --> 18:18.949
[SPEAKER_00]: In these 31 patients, they gave them four IV infusions, and the response rate was 77% at fourth week, and MSC's were obtained from bone marrow and of a young male.
18:19.590 --> 18:24.857
[SPEAKER_00]: So that's very encouraging, and then we go on to reproductive organs.
18:24.837 --> 18:39.116
[SPEAKER_00]: So premature ovarian failure in preclinical study of animals, the stem cell based therapies actually improved all the markers, FSH, the estrogen level ovarian weight, follicle count, and number of pregnancy.
18:39.136 --> 18:42.521
[SPEAKER_00]: So this is very encouraging for some of my female patients.
18:42.541 --> 18:51.773
[SPEAKER_00]: And after MSC treatment, when they looked at the ovarian size and endometrial thickness, they all have improved.
18:53.002 --> 18:54.045
[SPEAKER_00]: in aging ovaries.
18:54.065 --> 18:56.110
[SPEAKER_00]: So these are premenopausal rats.
18:56.912 --> 19:01.944
[SPEAKER_00]: And they were giving them either stem cells or control through IV route.
19:01.964 --> 19:08.901
[SPEAKER_00]: And they also showed decreased FSH and improved ovarian structure with increased follicle number.
19:10.535 --> 19:11.677
[SPEAKER_00]: and erectile dysfunction.
19:11.757 --> 19:14.842
[SPEAKER_00]: So we're all, they're familiar with the treatment of this.
19:14.882 --> 19:30.968
[SPEAKER_00]: All the animal studies have shown improved function and erectile dysfunction, whether or not is caused by the penal injury or a vascular insufficiency or diabetes or have a lipidemia or just aging.
19:31.649 --> 19:33.893
[SPEAKER_00]: One study shows seven men.
19:33.873 --> 19:44.724
[SPEAKER_00]: given a book of core blood stem cells, six out of seven returned their early morning erection in two months, and also increased penal hardness.
19:45.484 --> 19:51.891
[SPEAKER_00]: And they were able to respond to, you know, by Agra where they couldn't respond to it before.
19:52.351 --> 20:00.319
[SPEAKER_00]: And another study show bone marrow derived among nuclear cells, also were able to help people with vascular genic erectile dysfunction.
20:00.299 --> 20:07.862
[SPEAKER_00]: So nine out of 12 patients would be able to achieve successful intercourse so that's you know, that's amazing for these patients.
20:08.990 --> 20:16.136
[SPEAKER_00]: Another study, 17 men, refractory, post, prostitectomy, erectile dysfunction.
20:16.176 --> 20:22.302
[SPEAKER_00]: They were given autologous, adipose derived stem cells, and shows significant improvement noted at six months.
20:22.322 --> 20:23.223
[SPEAKER_00]: And this is really important.
20:23.363 --> 20:26.246
[SPEAKER_00]: Even though they didn't see any improvement at one and three months.
20:26.626 --> 20:28.047
[SPEAKER_00]: So, tail patients are hanging there.
20:28.227 --> 20:33.172
[SPEAKER_00]: Just because you didn't see anything one to three months, doesn't mean that hope is not down the line.
20:34.033 --> 20:38.997
[SPEAKER_00]: And some other studies also substantiate similar results.
20:38.977 --> 21:02.942
[SPEAKER_00]: And diabetic erectile dysfunction, so, you know, similar, you know, these are older patients, average age of 69 and they failed, you know, to have erection, despite medications and they were given a local cord blood stem cells and within one month morning erections were regained in three patients, so these are out of seven and by the third month, you know, six out of them have regained morning erection.
21:02.922 --> 21:11.559
[SPEAKER_00]: and also with increased rigidity and desire, and with improvement in blood sugar and decrease medication dose.
21:11.699 --> 21:13.603
[SPEAKER_00]: So hemoglobulin A1C is improved.
21:13.623 --> 21:17.611
[SPEAKER_00]: So it treated their erectile dysfunction and diabetes and pyrony.
21:17.651 --> 21:22.500
[SPEAKER_00]: So this is an inflammatory, you know, plaque forming disease, you know, with coverage of the
21:22.480 --> 21:37.578
[SPEAKER_00]: the penis and local injection using placental matrix derived MSCs were able to so right around in and around the plaque and they were able to out of the total 10 plaques, 7 disappeared completely at three months follow-up.
21:38.219 --> 21:44.607
[SPEAKER_00]: And I have that clinical experience as well, you know, very simple injection and complete resolution of the curvature.
21:44.587 --> 21:56.089
[SPEAKER_00]: So kidneys, Reno failure, in critical studies, they were able to show that for type 1 diabetes mice, a single IV dose MSC's led to recovery of renal function and pancreatic function.
21:57.211 --> 22:04.224
[SPEAKER_00]: And some studies also showed that bone marrow drive MSC's can reduce the fact of a schemic renal injury.
22:04.264 --> 22:07.590
[SPEAKER_00]: And even though MSC's do not,
22:07.570 --> 22:20.497
[SPEAKER_00]: really quite integrate long-term into the renal tubial cells, but they were able to help repair the renal system through the complex paracron and endocrine function.
22:20.797 --> 22:23.503
[SPEAKER_00]: So this is why I'm not stressing, you know,
22:23.483 --> 22:45.778
[SPEAKER_00]: whether or not the cells are identical to the human to the person the recipient is not crucial because we know nowadays with mountains of evidence how these cells work because so much of it is through paracrine and ocarine function because they function in the body as a signal and not exactly go into the place to differentiate but even for differentiation as you've seen human cells can differentiate into
22:45.758 --> 22:51.106
[SPEAKER_00]: You know, of course can't differentiate in in organ cells and survive in the animal body.
22:51.126 --> 22:55.694
[SPEAKER_00]: So even cross species is not uncommon, but cross humans is very common.
22:55.754 --> 23:01.743
[SPEAKER_00]: I don't know if you know, you know, we 60% of women actually carry why chromosomes in our body.
23:01.783 --> 23:10.117
[SPEAKER_00]: So between human, you know, within human species, having other people's DNA is really not something that's that dramatic and that incredible.
23:10.437 --> 23:12.340
[SPEAKER_00]: It's part of human history.
23:12.320 --> 23:18.327
[SPEAKER_00]: Another example, this is just a case study, 60-year-old woman.
23:18.387 --> 23:24.555
[SPEAKER_00]: She had chronic adrenal failure with, but she also had, you know, spinal cord entrapment.
23:25.836 --> 23:32.364
[SPEAKER_00]: So she, her creatinine level was 11 with no urination and she was given a local cord M.I.C.'
23:32.344 --> 23:36.389
[SPEAKER_00]: 's intrathecally and also intradenously three weeks later.
23:36.429 --> 23:40.234
[SPEAKER_00]: She was able to move her toes and her kidney function improved.
23:40.214 --> 23:46.258
[SPEAKER_00]: and her creatine level came down to 9 and after 8 months her creatine was 2 and she had normal urination.
23:46.930 --> 23:48.272
[SPEAKER_00]: okay moving on to liver.
23:49.754 --> 24:03.035
[SPEAKER_00]: So liver cirrhosis, so this is an animal model rat liver fibrosis model and rat was given human and blood core cord MSEs and they show significant reduction in liver fibrosis.
24:03.936 --> 24:10.026
[SPEAKER_00]: And the grafted human cells scattered, you know, in the tissue, but did not differentiate into hepatocyte.
24:10.046 --> 24:11.588
[SPEAKER_00]: So they didn't become
24:11.568 --> 24:18.439
[SPEAKER_00]: liver cells, but they were able to secrete all these bioactive cytokines that restore liver function.
24:20.444 --> 24:23.509
[SPEAKER_00]: Um, the end stage liver cirrhosis.
24:23.990 --> 24:31.782
[SPEAKER_00]: So these, uh, this is a human study, 51 patients, two thirds had a site ease, and one third had the hepatic, uh, in cephalopathy.
24:32.103 --> 24:34.347
[SPEAKER_00]: They were given them human, um, local corp less cells.
24:34.948 --> 24:47.548
[SPEAKER_00]: And after a single cell, uh, stem salt treatment, most of the hepatic in cephalopathy patients, and more than two thirds of the site patients improved in symptoms, uh, or responded to medical medication therapy that they were, refractory.
24:47.528 --> 24:48.489
[SPEAKER_00]: to previously.
24:48.589 --> 24:50.692
[SPEAKER_00]: They also improve their life expectancy.
24:52.254 --> 25:02.347
[SPEAKER_00]: Lungs at COPD, I love treating COPD patients because the results are so remarkable and it's so fun because that's the first place to sell go to and all these talk about the long trapping.
25:02.987 --> 25:10.096
[SPEAKER_00]: It just silly because initially, yes, it's well-prefused so the cells are going to be in the lungs and the liver in the spleen because that's, you know, hard.
25:10.417 --> 25:13.941
[SPEAKER_00]: That's where most of the profusion is, but the cells are not done.
25:13.921 --> 25:16.605
[SPEAKER_00]: So they don't stay in a place where they're not needed.
25:16.625 --> 25:23.956
[SPEAKER_00]: They will go to places once if the lung is normal and healthy, it's going to migrate.
25:24.176 --> 25:27.161
[SPEAKER_00]: And it's been shown to migrate systemically into other areas.
25:27.501 --> 25:32.048
[SPEAKER_00]: So you don't have to worry about the lung trapping unless your lungs are really needing help.
25:32.028 --> 25:49.648
[SPEAKER_00]: So, in this study intravenously or inter-peritoneal injection of, you know, again, human MSC's into rodents, they show significantly reduced airway inflammation, perancomal lung cell apoptosis, and also collagen deposition, so less fibrosis.
25:49.628 --> 25:56.050
[SPEAKER_00]: and intravenous infusion of autologous bone marrow cells into COPD patients, only four cases.
25:56.471 --> 26:02.271
[SPEAKER_00]: Talkman follow-up showed significant improvement in the quality of life as well as slowing down of disease process.
26:03.567 --> 26:08.994
[SPEAKER_00]: a long injury model, and Blocal Court MSCs were used, and they were given systemically.
26:10.717 --> 26:18.127
[SPEAKER_00]: So, injected MSCs were located in the lungs two weeks later, only in areas of the inflammation and fibrosis.
26:18.207 --> 26:20.971
[SPEAKER_00]: Again, they don't go and sit around and healthy long tissue.
26:21.291 --> 26:27.720
[SPEAKER_00]: They find a place where they actually needed, and the administration of these MSCs reduce inflammation.
26:27.760 --> 26:29.963
[SPEAKER_00]: They have anti-facrotic properties.
26:29.943 --> 26:39.332
[SPEAKER_00]: And I, so, so this is recognized as a pigmentosa, you know, usually a very very, you know, consider permanently, you know, permanent disability.
26:40.053 --> 26:44.997
[SPEAKER_00]: So they were able to inject intravenously into this rat model of retinitis pigmentosa.
26:45.998 --> 26:58.330
[SPEAKER_00]: And these injected cells from IV route migrated to the eye and possibly attracted by the chemocytes and, you know, secreted by the the retinum.
26:58.310 --> 27:03.022
[SPEAKER_00]: So visual function were actually significantly preserved comparing with controls.
27:03.884 --> 27:11.664
[SPEAKER_00]: And then, you know, it's demonstrated, there's neural protective effects from these cells, and also growth factors were upregulated.
27:11.704 --> 27:14.952
[SPEAKER_00]: So there's a protective neural effect.
27:16.315 --> 27:26.214
[SPEAKER_00]: In glaucoma, bone marrow drive MSEs were able to provide the survival of retina gangly in cells in the transplanted eye compared to the control.
27:26.835 --> 27:39.319
[SPEAKER_00]: So they were testing their ability to swim and these rats and these transplanted rats, you know, when they got bone marrow drive MSEs were able to perform much better.
27:39.299 --> 27:48.189
[SPEAKER_00]: So again, they show bone marrow derived stem cells as protective in H rats with retinal, gankly, and cell loss induced by glaucoma.
27:48.990 --> 27:50.232
[SPEAKER_00]: Macular degeneration.
27:52.074 --> 28:01.425
[SPEAKER_00]: So MSCs, so in this article, they were basically shown to see create these,
28:01.405 --> 28:12.140
[SPEAKER_00]: growth factors and they can provide neuroprotective effects and they can either inject into the eye or intravenous and they could, you know, both achieve the retinal protective effects.
28:12.641 --> 28:21.132
[SPEAKER_00]: And intravenously injected MSCs increase a survival of the photoreceptors and restored visual function by these rat models.
28:21.893 --> 28:30.265
[SPEAKER_00]: And so, it affects, again, was attributed to the secretion
28:30.245 --> 28:37.335
[SPEAKER_00]: And then they also downregulated the anti-apoptotic genes, so preserving some of the cells.
28:39.538 --> 28:43.584
[SPEAKER_00]: Year, so hearing, hearing laws, sensory, neural, hearing laws.
28:45.106 --> 28:50.274
[SPEAKER_00]: They were able to show using IV and Blocor blood rife stem cells, can enhance hearing threshold.
28:50.934 --> 28:58.345
[SPEAKER_00]: And the systemic infusion of human-adulted rife stem cells, significantly improved hearing function and protected hair cells.
28:59.371 --> 29:22.054
[SPEAKER_00]: And skin, you know, this is just one example, a pop talk dermatitis, but they're not as many studies on skin, but so this is a, you know, a top topic dermatitis, 34 patients, they were given the stem cells, I'm local core blood drive stem cells subcutaneously and there is a dose dependent improvement.
29:22.034 --> 29:28.742
[SPEAKER_00]: and they were able to show that the high dose of the MSCs were able to reduce the parieta score by 58%.
29:29.083 --> 29:32.587
[SPEAKER_00]: So they did downregulate the IGE levels.
29:34.289 --> 29:35.430
[SPEAKER_00]: Grafers is host disease.
29:35.490 --> 29:40.136
[SPEAKER_00]: So you guys all know that stem cells MSCs is powerful when it comes to graph versus host disease.
29:41.017 --> 29:46.624
[SPEAKER_00]: And what's fascinating is that even when there's
29:47.954 --> 30:02.512
[SPEAKER_00]: So I don't know, you probably all know that even if you perfectly match, so humanly matched cells or humanly match organs can still have a significant rejection rate because we're not matching all there is, you know, we're matching what we know.
30:03.774 --> 30:07.819
[SPEAKER_00]: But they were able to give MSCs
30:07.799 --> 30:15.689
[SPEAKER_00]: which is completely unmatched and that was able to reduce rejection rate and help reduce these graft versus host disease.
30:15.709 --> 30:27.124
[SPEAKER_00]: So that shows you the power of the MSCs that not only is immune evasive but is immune suppressive regardless of HLA compatibility.
30:28.623 --> 30:37.834
[SPEAKER_00]: Another study showed that 70% response rate overall and the complete response rate at 28 days was 77%.
30:37.874 --> 30:44.722
[SPEAKER_00]: So, and then here we have a study on HIV is very interesting.
30:45.022 --> 30:52.591
[SPEAKER_00]: So, these are people who are not responding to these, you know, anti-viral medications, 13 patients, they're not responders.
30:53.071 --> 30:58.157
[SPEAKER_00]: And they were given three on global court, MSCs.
30:58.137 --> 30:59.599
[SPEAKER_00]: transfusions.
31:00.641 --> 31:08.234
[SPEAKER_00]: And they were able to increase the patient's CD4 cell count and reduce systemic immune activation and inflammation.
31:08.254 --> 31:14.484
[SPEAKER_00]: So that is incredibly helpful for these people who otherwise was probably losing hope.
31:14.504 --> 31:15.606
[SPEAKER_00]: Autism.
31:15.586 --> 31:36.852
[SPEAKER_00]: So, these probably are the mechanisms why stem cells can help autism cases, so it can help improve endogenesis, modulating immune system, can reduce a popthosis, so reduce cell damage and to oxidant effect, modulate the excitation, you know, response, restore neuroconnectivity, stimulate, and dodge an stem cells.
31:36.832 --> 32:01.438
[SPEAKER_00]: And here's an article about the, so talked about, you know, 2013 studies showing some improvement in kids being treated with stem cells, showing improved eye contact social interactions, emotional responsiveness, speech and communication sensories, you know, a sensory, I guess a perception, attention and concentration and a hyperactivity aggressiveness.
32:01.418 --> 32:07.505
[SPEAKER_00]: So, they're a plenty of study showing more, you know, they're similar results.
32:08.546 --> 32:20.299
[SPEAKER_00]: And a study in 2013, using on local court, both on local court, stem cells, and local tissue stem cells, and local court blood stem cells.
32:20.339 --> 32:29.029
[SPEAKER_00]: What's interesting is that I love the study, the fact that they were looking at court blood, mononuclear cell group, and court,
32:29.009 --> 32:41.590
[SPEAKER_00]: And then a combination group and the control group, they did four infusions and they showed that the combination of the core blood plus the core tissue MSCs are the most powerful, have the best effect.
32:42.191 --> 32:44.875
[SPEAKER_00]: So I always believe that we want a comprehensive,
32:44.855 --> 32:45.536
[SPEAKER_00]: salt-type.
32:45.556 --> 32:52.423
[SPEAKER_00]: We want to bring the synergistic effects off these cells together, and this is another study I love.
32:53.565 --> 32:57.509
[SPEAKER_00]: We don't have a whole lot of good treatments of alcoholism.
32:57.649 --> 33:04.977
[SPEAKER_00]: I was a medical director for a few rehab centers in Malibu, and I've seen how difficult it is, and this is a really powerful study.
33:04.997 --> 33:07.420
[SPEAKER_00]: They were looking at these alcoholic rats.
33:07.400 --> 33:12.168
[SPEAKER_00]: and looking at how stem cell infusions can change that drinking behavior.
33:12.489 --> 33:20.663
[SPEAKER_00]: So they were giving them just free alcohol 10% for 73 days and then another 27 days of access to 10% or 20% drink as you wish.
33:21.344 --> 33:23.468
[SPEAKER_00]: And then they give them,
33:23.448 --> 33:26.712
[SPEAKER_00]: They actually injected into the cerebrum.
33:26.732 --> 33:31.998
[SPEAKER_00]: So they injected into the brain of these bone marrow derived MSCs or adipose derived MSCs.
33:32.558 --> 33:37.704
[SPEAKER_00]: And then they were allowed to drink either water or alcohol.
33:38.185 --> 33:42.109
[SPEAKER_00]: And they showed a significant reduction of alcohol intake.
33:42.810 --> 33:45.373
[SPEAKER_00]: And then they showed that.
33:46.374 --> 33:49.658
[SPEAKER_00]: So a single dose MSCs were able to reduce
33:49.638 --> 33:52.542
[SPEAKER_00]: the alcohol intake by 50% for 10 days.
33:52.703 --> 33:53.885
[SPEAKER_00]: So that's pretty remarkable.
33:54.445 --> 33:59.673
[SPEAKER_00]: And the second part of the study is really fun because they're really mimicking the rehab situation there.
33:59.694 --> 34:05.302
[SPEAKER_00]: They let these rats drink and drink and then all of a sudden they deprive them for 14 days.
34:05.322 --> 34:07.526
[SPEAKER_00]: So I was like putting them in rehab for 14 days.
34:07.826 --> 34:14.937
[SPEAKER_00]: So on day four of the deprivation, they give them either stem cells or a control, you know, placebo.
34:14.917 --> 34:19.863
[SPEAKER_00]: So, after 14 days, they let them to free intake alcohol.
34:20.163 --> 34:22.967
[SPEAKER_00]: So, they record how much alcohol they drink in 60 minutes.
34:23.387 --> 34:31.557
[SPEAKER_00]: And they were able to show that MSC-infused rats were able to drink about 80 to 85% less.
34:31.897 --> 34:33.018
[SPEAKER_00]: So, this is remarkable.
34:33.279 --> 34:44.552
[SPEAKER_00]: And their suspicion is that alcoholism is driven by neuronal inflammation by decreasing the inflammation
34:44.532 --> 34:45.373
[SPEAKER_00]: addiction behavior.
34:46.154 --> 34:48.597
[SPEAKER_00]: And the last one I want to talk about is anti aging.
34:48.617 --> 34:53.284
[SPEAKER_00]: So last year I actually did a presentation specifically on anti aging benefits of stem cells.
34:53.624 --> 34:59.052
[SPEAKER_00]: And this is area I'm passionate about because I want to help people to prevent the decline and to continue to be vibrant.
35:00.253 --> 35:02.256
[SPEAKER_00]: So I'm just going to give a few examples.
35:02.616 --> 35:06.542
[SPEAKER_00]: Of course, anti aging when you study life span is very difficult to study in people.
35:06.862 --> 35:09.105
[SPEAKER_00]: So you want to study in animals.
35:09.085 --> 35:10.947
[SPEAKER_00]: So the results has been pretty consistent.
35:11.228 --> 35:27.388
[SPEAKER_00]: We're able to see that the maximum lifespan in the stem cell treated mice were able to be increased by about 30 percent and the survival time were able to be increased by 3.5, a 3.2 fold.
35:27.629 --> 35:34.097
[SPEAKER_00]: So these are older rats when they start giving them stem cells even when they're older is
35:34.077 --> 35:39.164
[SPEAKER_00]: Giving them the remaining time, extending them basically, length of them by three times.
35:39.565 --> 35:44.992
[SPEAKER_00]: So that gives a lot of hope for people who are much older, but you're going to have a lot more time left.
35:45.032 --> 35:49.118
[SPEAKER_00]: And not only longer time left, but it's also better health span.
35:49.158 --> 35:50.020
[SPEAKER_00]: They look a lot better.
35:50.100 --> 35:50.741
[SPEAKER_00]: They're smarter.
35:51.121 --> 35:51.882
[SPEAKER_00]: They're more active.
35:51.922 --> 35:53.945
[SPEAKER_00]: They're just, you know, they're more vibrant.
35:54.446 --> 35:59.693
[SPEAKER_00]: And there's some chimerism, so which means the sum cells did integrate with a new organism.
35:59.994 --> 36:02.397
[SPEAKER_00]: And that's, to me, that's fine.
36:02.377 --> 36:09.172
[SPEAKER_00]: Another example, age rats, so 10 months old, so they just, you know, middle aged, they're aged.
36:09.192 --> 36:17.550
[SPEAKER_00]: And then they were giving them intravenous stem cells, and they, again, showed about, you know, 23 to 31% extension.
36:17.530 --> 36:32.832
[SPEAKER_00]: of their lifespan, and not only lifespan was extended, when they examined their brain and their muscles, the brain neurotrophot factors and the muscle neurotrophot factors both have been restored to a level higher than the younger rats.
36:33.753 --> 36:40.442
[SPEAKER_00]: And when they look at their number of blood vessels, the number of blood vessels were stored to equivalent to the younger rats.
36:40.462 --> 36:43.707
[SPEAKER_00]: So everything was restored to the younger state.
36:44.075 --> 36:48.762
[SPEAKER_00]: Um, so here is actually a human study, looking at 20 patients.
36:48.983 --> 37:01.342
[SPEAKER_00]: I think this is conducted in China, a looking at effect of anti-inflammatory effects and anti-aging effect, just one infusion, and then they measure some markers, and then, you know, at two weeks, three months, they look at how they did.
37:01.623 --> 37:07.973
[SPEAKER_00]: There's improvement in skin, hair, nail growth, energy level, libido, mood, sleep, and pain level.
37:07.953 --> 37:09.495
[SPEAKER_00]: Um, so that's that's it.
37:09.515 --> 37:20.952
[SPEAKER_00]: There's could be a lot more, but, you know, there's only 20 minutes, but I encourage anybody that's interested to take the, you know, American Academy, AICT.org.
37:20.972 --> 37:23.415
[SPEAKER_00]: So the course is on there as a their comprehensive course.
37:23.435 --> 37:30.045
[SPEAKER_00]: You get to take home over 300 articles and then, you know, you get different protocols and, you know, a lot of support from me.
37:30.025 --> 37:37.037
[SPEAKER_00]: Thank you for listening to this episode, hope you enjoy the content, and if so, please rate and follow this podcast.
37:37.057 --> 37:42.908
[SPEAKER_00]: To reach me, you can contact uplift longevity center, and that is uplift with a why.
37:43.168 --> 37:46.915
[SPEAKER_00]: You can also subscribe to my YouTube channel, Joy Kong, MD.
37:47.335 --> 37:48.237
[SPEAKER_00]: See you next time!
00:00.031 --> 00:17.099
[SPEAKER_00]: These probably are the mechanisms why stem cells can help autism cases, so it can help improve endogenesis, modulating immune system, can reduce apoptosis, so reduce cell damage, and to oxidant effect, modulate the excitation, response, and restore neuroconnectivity.
00:17.179 --> 00:19.823
[SPEAKER_00]: Welcome to the Dr. Duay Kong podcast.
00:19.843 --> 00:27.135
[SPEAKER_00]: This is where I have a chance to share with you some of the latest developments in the space of holistic health, longevity, and wellness.
00:27.115 --> 00:34.067
[SPEAKER_00]: I've always honored intellectual curiosity and scientific rigor, combined with real world practicality.
00:34.368 --> 00:38.776
[SPEAKER_00]: My goal is that what you learn here will help you live longer and live better.
00:39.076 --> 00:40.479
[SPEAKER_00]: Hope you enjoy the journey with me.
00:41.080 --> 00:45.327
[SPEAKER_00]: I think the purpose of this is really to talk about
00:46.083 --> 00:47.505
[SPEAKER_00]: What kind of evidence is there?
00:47.525 --> 00:57.442
[SPEAKER_00]: You know, we're all passionate about stem cell treatment, but what I've always been focusing on is what kind of evidence I can present to my patients.
00:58.243 --> 01:04.834
[SPEAKER_00]: And is actually pretty impressive how much evidence is out there.
01:04.814 --> 01:05.736
[SPEAKER_00]: have prepared.
01:05.756 --> 01:07.399
[SPEAKER_00]: It's going to be a lot of slide.
01:07.419 --> 01:08.901
[SPEAKER_00]: So I'm going to just be zooming through them.
01:09.562 --> 01:15.032
[SPEAKER_00]: But I just want to give you an idea of what's out there and what kind of conditions have been studied.
01:15.453 --> 01:24.308
[SPEAKER_00]: So you can take that back into your clinic and really, really help, you know, make some differences in places where maybe you, you didn't know that there's some evidence about.
01:24.288 --> 01:25.831
[SPEAKER_00]: stems off the treatments.
01:26.252 --> 01:30.320
[SPEAKER_00]: So yeah, so I found in American Academy of Integrated South Therapy.
01:30.981 --> 01:39.698
[SPEAKER_00]: I do we do have a clinical course called Fundamentals of stem cell practice where I go into more detail, but let's start.
01:39.678 --> 01:41.682
[SPEAKER_00]: So, first of all, autoimmune condition.
01:41.822 --> 01:48.034
[SPEAKER_00]: That's the one condition we know that one category we know that stem cell therapy has been powerful in.
01:48.655 --> 01:50.740
[SPEAKER_00]: And let's just take a look at first lupus.
01:51.140 --> 01:56.391
[SPEAKER_00]: So, this is using on local cord MICs in severe refractory lupus patients.
01:56.411 --> 01:57.653
[SPEAKER_00]: So, 16 patients.
01:57.633 --> 02:10.331
[SPEAKER_00]: There is significant decrease in disease severity and including improvement in markers and reduction in disease activity achieved in all these 60 patients with no recurrence three years later.
02:10.351 --> 02:12.133
[SPEAKER_00]: So that's pretty impressive.
02:12.574 --> 02:27.555
[SPEAKER_00]: And here's another study, 40 patients using on local court MICs in active and refractory loopous patients and they were able to see major clinical response
02:27.535 --> 02:32.662
[SPEAKER_00]: And on nine months, there are some railops rate and 12 months, you know, about 16% railops rate.
02:33.042 --> 02:38.650
[SPEAKER_00]: So their conclusion is that you likely require, require new infusion in about six months.
02:39.451 --> 02:40.512
[SPEAKER_00]: And rheumatoid arthritis.
02:40.932 --> 02:46.179
[SPEAKER_00]: So this is study again using a local core MSCs for people with active rheumatoid arthritis.
02:46.540 --> 02:49.003
[SPEAKER_00]: And there's significant remission
02:48.983 --> 03:06.874
[SPEAKER_00]: in all the MSC treatment groups, including improvement in their sleep, diet, physical strength to, you know, as soon as two weeks post treatment, and joints swelling were alleviated even within 12 hours and maintained throughout the study.
03:06.854 --> 03:08.638
[SPEAKER_00]: And here's inflammatory bowel disease.
03:09.560 --> 03:22.909
[SPEAKER_00]: Traditionally, we were using hematopuetic stem cells to treat patients, but that has various drawbacks, partially because you require chemotherapy and antibiotics and steroid.
03:22.929 --> 03:25.254
[SPEAKER_00]: It just, there are a lot of side effects.
03:25.975 --> 03:27.158
[SPEAKER_00]: And the new,
03:27.138 --> 03:47.078
[SPEAKER_00]: approach, probably a better approach is using mesenchymal stem cells, and you can do it locally or systemically, so here's an example of perinatal fistula, and local injections were able to help achieve 85.7% successful success rate in the healing of the fistula at 12 weeks.
03:47.839 --> 03:56.368
[SPEAKER_00]: And another example for Crohn's disease, using IV bone marrow derived stem cells, they were able to achieve
03:56.348 --> 04:03.258
[SPEAKER_00]: a end point that indicates remission in a 148 out of 207 patient.
04:03.298 --> 04:04.680
[SPEAKER_00]: So that's quite impressive.
04:05.642 --> 04:07.505
[SPEAKER_00]: For Crohn's disease, here's another study.
04:07.525 --> 04:13.814
[SPEAKER_00]: 82 patients, they were given IV infusions of the umbilical cord stem cells.
04:14.195 --> 04:21.225
[SPEAKER_00]: MSCs at 12 months, they show significant decrease in their symptoms and also decrease in the steroid dose.
04:22.218 --> 04:30.437
[SPEAKER_00]: So here's a visual picture of what you can see in the Mikoso layer and the improvement in the tissue.
04:30.878 --> 04:35.969
[SPEAKER_00]: School or a square or a Derma in refractures go to square or a Derma.
04:35.989 --> 04:39.096
[SPEAKER_00]: So this is only case study.
04:39.076 --> 04:54.141
[SPEAKER_00]: They were using a local core DMSC's and looking at actually patients achieving remission and they were able to sustain the results for 12 and 6 months.
04:54.682 --> 05:05.640
[SPEAKER_00]: And the second treatment, when they did it, they actually did not use any medications, any plasma for races, so they just gave stem cell straight and that still worked very well.
05:05.620 --> 05:07.062
[SPEAKER_00]: cardiovascular condition.
05:07.082 --> 05:09.205
[SPEAKER_00]: I'm going going to fast because there are a lot of conditions.
05:09.566 --> 05:24.287
[SPEAKER_00]: So athletes to growuses, these are so some studies mice were treated with MSCs and they were able to show reduction in the plaques and also inflammatory markers.
05:24.267 --> 05:31.628
[SPEAKER_00]: and they were able to reduce cholesterol and able to reduce the bascular lesion by 33% in the aortic root.
05:31.949 --> 05:36.803
[SPEAKER_00]: So here you can see a visual lesion size decrease and macrophage content decrease at the site.
05:37.525 --> 05:39.390
[SPEAKER_00]: Myocardial infarction.
05:39.370 --> 05:42.034
[SPEAKER_00]: human and local court blood transplanting.
05:43.076 --> 05:44.999
[SPEAKER_00]: So this is a first one is a mice study.
05:45.019 --> 05:52.091
[SPEAKER_00]: They showed reduced infarct volume with 20% higher capillary density around the infarct area.
05:52.131 --> 06:03.049
[SPEAKER_00]: So that shows, you know, recovery of the tissue, 2006 rat study and local court blood cells was able to colonize in the infarct area.
06:03.029 --> 06:21.173
[SPEAKER_00]: and what's fascinating, this is a rat, and they showed the cells around the blood vessels were actually of human origin, so they were actually settling down in a different species, and still was able to help, you know, help, you know,
06:21.878 --> 06:23.180
[SPEAKER_00]: the regeneration.
06:23.740 --> 06:36.117
[SPEAKER_00]: And the RAS study in 2009 also showed, you know, some correlation with higher veggie levels and the cells were able to concentrate in in farce area.
06:36.137 --> 06:43.887
[SPEAKER_00]: So their conclusion was IV infusion actually was a adequate strategy for treating the heart.
06:45.638 --> 06:46.739
[SPEAKER_00]: Okay, I'm sorry, I went back.
06:47.280 --> 06:48.641
[SPEAKER_00]: Okay, here's another study.
06:50.162 --> 06:57.990
[SPEAKER_00]: Looking at MSC's, how it helps the recovery in breaking down scar tissue after MI.
06:58.710 --> 07:07.699
[SPEAKER_00]: And two months after MSC treatment, the exchemic heart showed large improvement in left-end curricular anterior walled thickness in the infarct area.
07:08.420 --> 07:11.583
[SPEAKER_00]: And of course, the ejection fraction was improved.
07:12.043 --> 07:14.025
[SPEAKER_00]: And congested part failure,
07:14.005 --> 07:29.245
[SPEAKER_00]: Um, intravenous infusion of emblocal cord MSCs in heart failure patients were able to show that the treatment group was improved in left-on-tricular function and quality of life at three six and twelve months follow-up.
07:29.265 --> 07:34.512
[SPEAKER_00]: Um, so it decreased their hospitalization and decreased their arithmetic events.
07:34.492 --> 07:37.234
[SPEAKER_00]: And here's another congested heart failure.
07:38.075 --> 07:45.341
[SPEAKER_00]: Some more studies showing the allergenic cells actually increase Levantricular ejection fractions significantly.
07:45.862 --> 07:54.569
[SPEAKER_00]: And MSCs from either adipose or bone marrow do not increase the Levantricular ejection fraction compared to controls.
07:55.070 --> 08:04.498
[SPEAKER_00]: So in this case, the allergenic controlled a higher efficacy.
08:04.478 --> 08:11.326
[SPEAKER_00]: either around the heart, right around the heart, or intravenously, do not show that much difference in the improvement.
08:11.686 --> 08:12.727
[SPEAKER_00]: So that's really interesting.
08:12.747 --> 08:27.343
[SPEAKER_00]: And this is why I'm so excited, and you know, because such an elegant approach to give people an IV treatment because I do count on the natural intelligence of the cells to find the areas where they're needed and we can see more of the evidence as I go through other organ systems.
08:28.665 --> 08:29.145
[SPEAKER_00]: Diabetes.
08:29.746 --> 08:31.448
[SPEAKER_00]: So type one diabetes.
08:31.428 --> 08:48.188
[SPEAKER_00]: 29 patients, newly onset type 1 diabetes, they were given 2 infusions for weeks apart and they were able to show improvement in hemoglobin A1C and C peptide in these patients comparing to before the treatment or comparing to placebo group.
08:48.168 --> 08:57.269
[SPEAKER_00]: and another study using Wharton Jelly, MSC, and they were able to show that these MSC could, even though they're called methanchymal stem cells, right?
08:57.289 --> 09:05.046
[SPEAKER_00]: So they're supposed to be from Mesoderm layer, but they can cross this germ layer, you know, differences.
09:05.026 --> 09:08.590
[SPEAKER_00]: and differentiate into insulin-producing cells.
09:08.670 --> 09:10.532
[SPEAKER_00]: So that's pretty cool, pretty exciting.
09:11.714 --> 09:18.742
[SPEAKER_00]: So after MIC transplantation, what's fascinating is that some of these insulin-producing cells were located in the liver.
09:19.383 --> 09:24.288
[SPEAKER_00]: And still, even though they were in the liver, they were still able to normalize the hypergalicemia.
09:25.089 --> 09:34.240
[SPEAKER_00]: And warden's jelly MSEs can be differentiated better than bone marrow MSEs toward the mature beta cell type.
09:34.658 --> 09:35.879
[SPEAKER_00]: and type two diabetes.
09:36.500 --> 09:43.968
[SPEAKER_00]: So this is study showing 22 patients, given IV injection, plus intra-pancreatic injection.
09:44.508 --> 10:02.607
[SPEAKER_00]: And they were able to use the umbilical cord, I mean, what in jelly MSCs, they were able to significantly decrease the level of blood sugar and hemocopent A1C and improve CPAP-type levels, showing that nurse better beta-false cell function and reduce marker of systemic inflammation.
10:02.587 --> 10:13.860
[SPEAKER_00]: the hemoglobulin A1C level was lowest at three months post treatment, but the improvement was sustained at 12 months, so that shows the long-term benefit of these stem-salt treatments.
10:13.880 --> 10:19.886
[SPEAKER_00]: And here's another study, adult, allergenic, bone marrow-derived MSC's MSC precursor cells.
10:19.906 --> 10:21.809
[SPEAKER_00]: So this is something that's similar to MSC's.
10:22.970 --> 10:30.298
[SPEAKER_00]: They when compared with placebo's, these the patients who
10:30.278 --> 10:39.587
[SPEAKER_00]: or given the some cells were able to reduce hemoglobin A1C, so just more proof.
10:39.607 --> 10:40.868
[SPEAKER_00]: And then we come to neurological.
10:40.928 --> 10:56.944
[SPEAKER_00]: So a hemorrhage stroke, we can use intravenently transclanity, human and local core cells, which when they were given intravenously, they could migrate selectively to the area of the lesion.
10:57.633 --> 11:01.458
[SPEAKER_00]: and result in better functional tests performance in seven and 14 weeks.
11:01.518 --> 11:04.581
[SPEAKER_00]: So again, intravenous, the cells and intelligence would guide them there.
11:04.621 --> 11:12.311
[SPEAKER_00]: And for here's an exchemic stroke using autologous bone marrow MSCs.
11:12.991 --> 11:18.097
[SPEAKER_00]: And they were able to show functional recovery more frequently than control.
11:18.838 --> 11:26.948
[SPEAKER_00]: And the cumulative survival rate was much higher, so twice as high in the treatment group than the control group.
11:26.928 --> 11:30.072
[SPEAKER_00]: And spinal cord injury, we're talking about spinal cord injury.
11:30.092 --> 11:36.679
[SPEAKER_00]: So here's a study on a vocal cord derived stem cells, 25 patients.
11:36.739 --> 11:40.183
[SPEAKER_00]: They were given both intravenous and then later on intrathecal.
11:40.544 --> 11:45.309
[SPEAKER_00]: So I 12 months after treatment, there's some improvements.
11:45.449 --> 11:53.138
[SPEAKER_00]: So I wish it's higher, but I think in spinal cord injury cases, the expectation is more tempered.
11:53.118 --> 12:14.687
[SPEAKER_00]: which was why it's so exciting to see what they're doing in China, so here you can see 16% showed improvement in the American's final injury association score and spasm decrees in 28 percent of patients and then autumn non-function improve in 32 percent and there's some 24 percent had improved urinary function.
12:15.477 --> 12:20.884
[SPEAKER_00]: And in traumatic brain injury, MSCs do have the ability to cross the endothelial layer.
12:20.904 --> 12:22.265
[SPEAKER_00]: So cross the blood brain barrier.
12:22.285 --> 12:23.527
[SPEAKER_00]: So a lot of people don't know.
12:23.587 --> 12:27.992
[SPEAKER_00]: They think that MSCs, because their cells, their stem cells, they can't cross the blood brain barrier.
12:28.233 --> 12:36.303
[SPEAKER_00]: But no, MSCs actually have a particular capability to integrate into the endothelium and then cross the layer.
12:36.843 --> 12:42.430
[SPEAKER_00]: And so they were able to influence the tight junction barrier.
12:42.410 --> 12:45.273
[SPEAKER_00]: and they're able to decrease inflammation.
12:45.313 --> 12:48.677
[SPEAKER_00]: So this is an important property of MSEs.
12:49.498 --> 12:56.286
[SPEAKER_00]: So here's a lot of pre-clinical studies showing bone marrow and mononuclear cells improving TBI outcomes.
12:57.067 --> 13:08.100
[SPEAKER_00]: And in a phase one study of children with severe TBI, they were showing that there is not only safety, but also central nervous system, structural preservation type of effect.
13:08.620 --> 13:11.944
[SPEAKER_00]: Another study of 25 adults with severe TBI,
13:11.924 --> 13:25.885
[SPEAKER_00]: And this is within 36 hours injury, they were able to show that with stem salt treatment, there were structural preservation and critical regions that were correlated with functional outcome.
13:26.526 --> 13:32.174
[SPEAKER_00]: And they also were able to downregulate inflammatory biomarkers.
13:32.995 --> 13:38.083
[SPEAKER_00]: And when infused intravenously, these cells,
13:38.063 --> 13:49.318
[SPEAKER_00]: are able to have similar methods of action whether or not by dampening the innate immune system.
13:49.358 --> 13:57.709
[SPEAKER_00]: So I think we just need to keep in mind that the power of IV infusions because not only
13:57.689 --> 14:07.281
[SPEAKER_00]: It will travel to the site of injury, but it's also going to talk with your entire immune system and invoke the help of your spleen and your peripheral lymphoy system.
14:07.361 --> 14:11.546
[SPEAKER_00]: So I don't think we can underestimate the power of your entire body.
14:11.807 --> 14:26.565
[SPEAKER_00]: Instead of focusing on local injection, this is why I think even for central nervous systems is, you know, intranazzo is a great method, but I think it's important to still bring the power of your systemic of your entire body into place.
14:27.794 --> 14:39.279
[SPEAKER_00]: Another study, this is an animal study, MSC's can selectively migrate to injury-brain areas, and differentiate into neurons and aftersites.
14:39.299 --> 14:47.878
[SPEAKER_00]: So that's another thing that, you know, that even though their measled germ cells, right, messin' kymos times cells, but they can differentiate into neurotissue.
14:47.858 --> 15:05.580
[SPEAKER_00]: And another study showed that after MSC treatment, the different growth factors, the nerve growth factor, brain-dravener, neurotropic factor, were significantly increased during six-month follow-up and correlating with neurological function improvement.
15:05.560 --> 15:06.381
[SPEAKER_00]: and migraines.
15:06.742 --> 15:13.913
[SPEAKER_00]: So these are very severely ill patients, sometimes have daily or even twice daily migraines.
15:14.213 --> 15:16.296
[SPEAKER_00]: So this is a small study.
15:16.376 --> 15:17.138
[SPEAKER_00]: Only four women.
15:17.478 --> 15:23.367
[SPEAKER_00]: They were giving them IV, strumovascular fraction, and all experienced dramatic improvements.
15:23.347 --> 15:27.393
[SPEAKER_00]: some required repeat infusions seven to 18 months after.
15:28.114 --> 15:34.564
[SPEAKER_00]: And then another study had nine patients and they also show some benefit, but they were doing IAM injections.
15:35.405 --> 15:42.977
[SPEAKER_00]: So these did not produce as profound of the effect as studies using IV SVF.
15:42.997 --> 15:48.044
[SPEAKER_00]: So I think that probably speaks to the power of the intravenous method.
15:49.567 --> 15:51.109
[SPEAKER_00]: Orthopedic conditions.
15:51.342 --> 15:55.007
[SPEAKER_00]: Um, I love this study because it's so powerful.
15:55.392 --> 16:04.703
[SPEAKER_00]: So basically, 30 patients, they all has steroid induced osteo-necrosis.
16:04.723 --> 16:07.506
[SPEAKER_00]: So bones are going dead in both knees.
16:07.906 --> 16:11.430
[SPEAKER_00]: So they would need typically bilateral knee replacement.
16:11.851 --> 16:16.676
[SPEAKER_00]: But what they did was they divide the patient from the center line.
16:16.996 --> 16:19.479
[SPEAKER_00]: So they would do one knee replaced.
16:19.820 --> 16:23.644
[SPEAKER_00]: The other knee inject, I think bone marrow derived stem cells.
16:23.624 --> 16:24.766
[SPEAKER_00]: and look at the outcome.
16:24.786 --> 16:34.179
[SPEAKER_00]: So what happened was really fascinating is that at 12-year follow-up, six of the 30 total knee replacement patients actually needed a revision surgery.
16:34.560 --> 16:37.584
[SPEAKER_00]: So still, you know, six out of 30, that's one fifth.
16:38.005 --> 16:44.494
[SPEAKER_00]: But the knee that only got bone marrow derived stem cells, only one actually needed surgery at all.
16:44.755 --> 16:46.257
[SPEAKER_00]: So this is a very powerful study.
16:47.637 --> 16:48.899
[SPEAKER_00]: degenerative disc disease.
16:49.220 --> 16:55.249
[SPEAKER_00]: So some studies have shown that MSCs can restore disc height and function and improve symptoms.
16:55.269 --> 16:57.793
[SPEAKER_00]: Another study was looking at 10 patients.
16:57.933 --> 17:04.904
[SPEAKER_00]: Autologous expanded MSCs injected into the nucleus and showed rapid improvement in pain and disability.
17:05.826 --> 17:14.860
[SPEAKER_00]: And so a local cord MSCs, they actually could induce synthesis of proteoglycans and restore distructure.
17:15.785 --> 17:28.477
[SPEAKER_00]: A Vasculine Ecrosis, stem cells, so whether or not it's early disease or a later stage disease does have something to do with how patient and how well they do with stem cell treatment.
17:28.497 --> 17:44.813
[SPEAKER_00]: So it is early pre-collapse type disease in a Vasculine Ecrosis of the hip, you know, at the femoral head, only 9 out of 145 of those hips actually required total hip replacement.
17:44.793 --> 17:51.946
[SPEAKER_00]: you know, more than half act will end it up require total hip replacement and collizing sponolitis.
17:53.189 --> 18:02.807
[SPEAKER_00]: These are, of course, inflammatory disease and, you know, their suspicions that they actually have dysfunctional MSC.
18:02.827 --> 18:04.590
[SPEAKER_00]: So these patients have impaired.
18:04.570 --> 18:06.513
[SPEAKER_00]: in the regulatory capabilities.
18:07.193 --> 18:18.949
[SPEAKER_00]: In these 31 patients, they gave them four IV infusions, and the response rate was 77% at fourth week, and MSC's were obtained from bone marrow and of a young male.
18:19.590 --> 18:24.857
[SPEAKER_00]: So that's very encouraging, and then we go on to reproductive organs.
18:24.837 --> 18:39.116
[SPEAKER_00]: So premature ovarian failure in preclinical study of animals, the stem cell based therapies actually improved all the markers, FSH, the estrogen level ovarian weight, follicle count, and number of pregnancy.
18:39.136 --> 18:42.521
[SPEAKER_00]: So this is very encouraging for some of my female patients.
18:42.541 --> 18:51.773
[SPEAKER_00]: And after MSC treatment, when they looked at the ovarian size and endometrial thickness, they all have improved.
18:53.002 --> 18:54.045
[SPEAKER_00]: in aging ovaries.
18:54.065 --> 18:56.110
[SPEAKER_00]: So these are premenopausal rats.
18:56.912 --> 19:01.944
[SPEAKER_00]: And they were giving them either stem cells or control through IV route.
19:01.964 --> 19:08.901
[SPEAKER_00]: And they also showed decreased FSH and improved ovarian structure with increased follicle number.
19:10.535 --> 19:11.677
[SPEAKER_00]: and erectile dysfunction.
19:11.757 --> 19:14.842
[SPEAKER_00]: So we're all, they're familiar with the treatment of this.
19:14.882 --> 19:30.968
[SPEAKER_00]: All the animal studies have shown improved function and erectile dysfunction, whether or not is caused by the penal injury or a vascular insufficiency or diabetes or have a lipidemia or just aging.
19:31.649 --> 19:33.893
[SPEAKER_00]: One study shows seven men.
19:33.873 --> 19:44.724
[SPEAKER_00]: given a book of core blood stem cells, six out of seven returned their early morning erection in two months, and also increased penal hardness.
19:45.484 --> 19:51.891
[SPEAKER_00]: And they were able to respond to, you know, by Agra where they couldn't respond to it before.
19:52.351 --> 20:00.319
[SPEAKER_00]: And another study show bone marrow derived among nuclear cells, also were able to help people with vascular genic erectile dysfunction.
20:00.299 --> 20:07.862
[SPEAKER_00]: So nine out of 12 patients would be able to achieve successful intercourse so that's you know, that's amazing for these patients.
20:08.990 --> 20:16.136
[SPEAKER_00]: Another study, 17 men, refractory, post, prostitectomy, erectile dysfunction.
20:16.176 --> 20:22.302
[SPEAKER_00]: They were given autologous, adipose derived stem cells, and shows significant improvement noted at six months.
20:22.322 --> 20:23.223
[SPEAKER_00]: And this is really important.
20:23.363 --> 20:26.246
[SPEAKER_00]: Even though they didn't see any improvement at one and three months.
20:26.626 --> 20:28.047
[SPEAKER_00]: So, tail patients are hanging there.
20:28.227 --> 20:33.172
[SPEAKER_00]: Just because you didn't see anything one to three months, doesn't mean that hope is not down the line.
20:34.033 --> 20:38.997
[SPEAKER_00]: And some other studies also substantiate similar results.
20:38.977 --> 21:02.942
[SPEAKER_00]: And diabetic erectile dysfunction, so, you know, similar, you know, these are older patients, average age of 69 and they failed, you know, to have erection, despite medications and they were given a local cord blood stem cells and within one month morning erections were regained in three patients, so these are out of seven and by the third month, you know, six out of them have regained morning erection.
21:02.922 --> 21:11.559
[SPEAKER_00]: and also with increased rigidity and desire, and with improvement in blood sugar and decrease medication dose.
21:11.699 --> 21:13.603
[SPEAKER_00]: So hemoglobulin A1C is improved.
21:13.623 --> 21:17.611
[SPEAKER_00]: So it treated their erectile dysfunction and diabetes and pyrony.
21:17.651 --> 21:22.500
[SPEAKER_00]: So this is an inflammatory, you know, plaque forming disease, you know, with coverage of the
21:22.480 --> 21:37.578
[SPEAKER_00]: the penis and local injection using placental matrix derived MSCs were able to so right around in and around the plaque and they were able to out of the total 10 plaques, 7 disappeared completely at three months follow-up.
21:38.219 --> 21:44.607
[SPEAKER_00]: And I have that clinical experience as well, you know, very simple injection and complete resolution of the curvature.
21:44.587 --> 21:56.089
[SPEAKER_00]: So kidneys, Reno failure, in critical studies, they were able to show that for type 1 diabetes mice, a single IV dose MSC's led to recovery of renal function and pancreatic function.
21:57.211 --> 22:04.224
[SPEAKER_00]: And some studies also showed that bone marrow drive MSC's can reduce the fact of a schemic renal injury.
22:04.264 --> 22:07.590
[SPEAKER_00]: And even though MSC's do not,
22:07.570 --> 22:20.497
[SPEAKER_00]: really quite integrate long-term into the renal tubial cells, but they were able to help repair the renal system through the complex paracron and endocrine function.
22:20.797 --> 22:23.503
[SPEAKER_00]: So this is why I'm not stressing, you know,
22:23.483 --> 22:45.778
[SPEAKER_00]: whether or not the cells are identical to the human to the person the recipient is not crucial because we know nowadays with mountains of evidence how these cells work because so much of it is through paracrine and ocarine function because they function in the body as a signal and not exactly go into the place to differentiate but even for differentiation as you've seen human cells can differentiate into
22:45.758 --> 22:51.106
[SPEAKER_00]: You know, of course can't differentiate in in organ cells and survive in the animal body.
22:51.126 --> 22:55.694
[SPEAKER_00]: So even cross species is not uncommon, but cross humans is very common.
22:55.754 --> 23:01.743
[SPEAKER_00]: I don't know if you know, you know, we 60% of women actually carry why chromosomes in our body.
23:01.783 --> 23:10.117
[SPEAKER_00]: So between human, you know, within human species, having other people's DNA is really not something that's that dramatic and that incredible.
23:10.437 --> 23:12.340
[SPEAKER_00]: It's part of human history.
23:12.320 --> 23:18.327
[SPEAKER_00]: Another example, this is just a case study, 60-year-old woman.
23:18.387 --> 23:24.555
[SPEAKER_00]: She had chronic adrenal failure with, but she also had, you know, spinal cord entrapment.
23:25.836 --> 23:32.364
[SPEAKER_00]: So she, her creatinine level was 11 with no urination and she was given a local cord M.I.C.'
23:32.344 --> 23:36.389
[SPEAKER_00]: 's intrathecally and also intradenously three weeks later.
23:36.429 --> 23:40.234
[SPEAKER_00]: She was able to move her toes and her kidney function improved.
23:40.214 --> 23:46.258
[SPEAKER_00]: and her creatine level came down to 9 and after 8 months her creatine was 2 and she had normal urination.
23:46.930 --> 23:48.272
[SPEAKER_00]: okay moving on to liver.
23:49.754 --> 24:03.035
[SPEAKER_00]: So liver cirrhosis, so this is an animal model rat liver fibrosis model and rat was given human and blood core cord MSEs and they show significant reduction in liver fibrosis.
24:03.936 --> 24:10.026
[SPEAKER_00]: And the grafted human cells scattered, you know, in the tissue, but did not differentiate into hepatocyte.
24:10.046 --> 24:11.588
[SPEAKER_00]: So they didn't become
24:11.568 --> 24:18.439
[SPEAKER_00]: liver cells, but they were able to secrete all these bioactive cytokines that restore liver function.
24:20.444 --> 24:23.509
[SPEAKER_00]: Um, the end stage liver cirrhosis.
24:23.990 --> 24:31.782
[SPEAKER_00]: So these, uh, this is a human study, 51 patients, two thirds had a site ease, and one third had the hepatic, uh, in cephalopathy.
24:32.103 --> 24:34.347
[SPEAKER_00]: They were given them human, um, local corp less cells.
24:34.948 --> 24:47.548
[SPEAKER_00]: And after a single cell, uh, stem salt treatment, most of the hepatic in cephalopathy patients, and more than two thirds of the site patients improved in symptoms, uh, or responded to medical medication therapy that they were, refractory.
24:47.528 --> 24:48.489
[SPEAKER_00]: to previously.
24:48.589 --> 24:50.692
[SPEAKER_00]: They also improve their life expectancy.
24:52.254 --> 25:02.347
[SPEAKER_00]: Lungs at COPD, I love treating COPD patients because the results are so remarkable and it's so fun because that's the first place to sell go to and all these talk about the long trapping.
25:02.987 --> 25:10.096
[SPEAKER_00]: It just silly because initially, yes, it's well-prefused so the cells are going to be in the lungs and the liver in the spleen because that's, you know, hard.
25:10.417 --> 25:13.941
[SPEAKER_00]: That's where most of the profusion is, but the cells are not done.
25:13.921 --> 25:16.605
[SPEAKER_00]: So they don't stay in a place where they're not needed.
25:16.625 --> 25:23.956
[SPEAKER_00]: They will go to places once if the lung is normal and healthy, it's going to migrate.
25:24.176 --> 25:27.161
[SPEAKER_00]: And it's been shown to migrate systemically into other areas.
25:27.501 --> 25:32.048
[SPEAKER_00]: So you don't have to worry about the lung trapping unless your lungs are really needing help.
25:32.028 --> 25:49.648
[SPEAKER_00]: So, in this study intravenously or inter-peritoneal injection of, you know, again, human MSC's into rodents, they show significantly reduced airway inflammation, perancomal lung cell apoptosis, and also collagen deposition, so less fibrosis.
25:49.628 --> 25:56.050
[SPEAKER_00]: and intravenous infusion of autologous bone marrow cells into COPD patients, only four cases.
25:56.471 --> 26:02.271
[SPEAKER_00]: Talkman follow-up showed significant improvement in the quality of life as well as slowing down of disease process.
26:03.567 --> 26:08.994
[SPEAKER_00]: a long injury model, and Blocal Court MSCs were used, and they were given systemically.
26:10.717 --> 26:18.127
[SPEAKER_00]: So, injected MSCs were located in the lungs two weeks later, only in areas of the inflammation and fibrosis.
26:18.207 --> 26:20.971
[SPEAKER_00]: Again, they don't go and sit around and healthy long tissue.
26:21.291 --> 26:27.720
[SPEAKER_00]: They find a place where they actually needed, and the administration of these MSCs reduce inflammation.
26:27.760 --> 26:29.963
[SPEAKER_00]: They have anti-facrotic properties.
26:29.943 --> 26:39.332
[SPEAKER_00]: And I, so, so this is recognized as a pigmentosa, you know, usually a very very, you know, consider permanently, you know, permanent disability.
26:40.053 --> 26:44.997
[SPEAKER_00]: So they were able to inject intravenously into this rat model of retinitis pigmentosa.
26:45.998 --> 26:58.330
[SPEAKER_00]: And these injected cells from IV route migrated to the eye and possibly attracted by the chemocytes and, you know, secreted by the the retinum.
26:58.310 --> 27:03.022
[SPEAKER_00]: So visual function were actually significantly preserved comparing with controls.
27:03.884 --> 27:11.664
[SPEAKER_00]: And then, you know, it's demonstrated, there's neural protective effects from these cells, and also growth factors were upregulated.
27:11.704 --> 27:14.952
[SPEAKER_00]: So there's a protective neural effect.
27:16.315 --> 27:26.214
[SPEAKER_00]: In glaucoma, bone marrow drive MSEs were able to provide the survival of retina gangly in cells in the transplanted eye compared to the control.
27:26.835 --> 27:39.319
[SPEAKER_00]: So they were testing their ability to swim and these rats and these transplanted rats, you know, when they got bone marrow drive MSEs were able to perform much better.
27:39.299 --> 27:48.189
[SPEAKER_00]: So again, they show bone marrow derived stem cells as protective in H rats with retinal, gankly, and cell loss induced by glaucoma.
27:48.990 --> 27:50.232
[SPEAKER_00]: Macular degeneration.
27:52.074 --> 28:01.425
[SPEAKER_00]: So MSCs, so in this article, they were basically shown to see create these,
28:01.405 --> 28:12.140
[SPEAKER_00]: growth factors and they can provide neuroprotective effects and they can either inject into the eye or intravenous and they could, you know, both achieve the retinal protective effects.
28:12.641 --> 28:21.132
[SPEAKER_00]: And intravenously injected MSCs increase a survival of the photoreceptors and restored visual function by these rat models.
28:21.893 --> 28:30.265
[SPEAKER_00]: And so, it affects, again, was attributed to the secretion
28:30.245 --> 28:37.335
[SPEAKER_00]: And then they also downregulated the anti-apoptotic genes, so preserving some of the cells.
28:39.538 --> 28:43.584
[SPEAKER_00]: Year, so hearing, hearing laws, sensory, neural, hearing laws.
28:45.106 --> 28:50.274
[SPEAKER_00]: They were able to show using IV and Blocor blood rife stem cells, can enhance hearing threshold.
28:50.934 --> 28:58.345
[SPEAKER_00]: And the systemic infusion of human-adulted rife stem cells, significantly improved hearing function and protected hair cells.
28:59.371 --> 29:22.054
[SPEAKER_00]: And skin, you know, this is just one example, a pop talk dermatitis, but they're not as many studies on skin, but so this is a, you know, a top topic dermatitis, 34 patients, they were given the stem cells, I'm local core blood drive stem cells subcutaneously and there is a dose dependent improvement.
29:22.034 --> 29:28.742
[SPEAKER_00]: and they were able to show that the high dose of the MSCs were able to reduce the parieta score by 58%.
29:29.083 --> 29:32.587
[SPEAKER_00]: So they did downregulate the IGE levels.
29:34.289 --> 29:35.430
[SPEAKER_00]: Grafers is host disease.
29:35.490 --> 29:40.136
[SPEAKER_00]: So you guys all know that stem cells MSCs is powerful when it comes to graph versus host disease.
29:41.017 --> 29:46.624
[SPEAKER_00]: And what's fascinating is that even when there's
29:47.954 --> 30:02.512
[SPEAKER_00]: So I don't know, you probably all know that even if you perfectly match, so humanly matched cells or humanly match organs can still have a significant rejection rate because we're not matching all there is, you know, we're matching what we know.
30:03.774 --> 30:07.819
[SPEAKER_00]: But they were able to give MSCs
30:07.799 --> 30:15.689
[SPEAKER_00]: which is completely unmatched and that was able to reduce rejection rate and help reduce these graft versus host disease.
30:15.709 --> 30:27.124
[SPEAKER_00]: So that shows you the power of the MSCs that not only is immune evasive but is immune suppressive regardless of HLA compatibility.
30:28.623 --> 30:37.834
[SPEAKER_00]: Another study showed that 70% response rate overall and the complete response rate at 28 days was 77%.
30:37.874 --> 30:44.722
[SPEAKER_00]: So, and then here we have a study on HIV is very interesting.
30:45.022 --> 30:52.591
[SPEAKER_00]: So, these are people who are not responding to these, you know, anti-viral medications, 13 patients, they're not responders.
30:53.071 --> 30:58.157
[SPEAKER_00]: And they were given three on global court, MSCs.
30:58.137 --> 30:59.599
[SPEAKER_00]: transfusions.
31:00.641 --> 31:08.234
[SPEAKER_00]: And they were able to increase the patient's CD4 cell count and reduce systemic immune activation and inflammation.
31:08.254 --> 31:14.484
[SPEAKER_00]: So that is incredibly helpful for these people who otherwise was probably losing hope.
31:14.504 --> 31:15.606
[SPEAKER_00]: Autism.
31:15.586 --> 31:36.852
[SPEAKER_00]: So, these probably are the mechanisms why stem cells can help autism cases, so it can help improve endogenesis, modulating immune system, can reduce a popthosis, so reduce cell damage and to oxidant effect, modulate the excitation, you know, response, restore neuroconnectivity, stimulate, and dodge an stem cells.
31:36.832 --> 32:01.438
[SPEAKER_00]: And here's an article about the, so talked about, you know, 2013 studies showing some improvement in kids being treated with stem cells, showing improved eye contact social interactions, emotional responsiveness, speech and communication sensories, you know, a sensory, I guess a perception, attention and concentration and a hyperactivity aggressiveness.
32:01.418 --> 32:07.505
[SPEAKER_00]: So, they're a plenty of study showing more, you know, they're similar results.
32:08.546 --> 32:20.299
[SPEAKER_00]: And a study in 2013, using on local court, both on local court, stem cells, and local tissue stem cells, and local court blood stem cells.
32:20.339 --> 32:29.029
[SPEAKER_00]: What's interesting is that I love the study, the fact that they were looking at court blood, mononuclear cell group, and court,
32:29.009 --> 32:41.590
[SPEAKER_00]: And then a combination group and the control group, they did four infusions and they showed that the combination of the core blood plus the core tissue MSCs are the most powerful, have the best effect.
32:42.191 --> 32:44.875
[SPEAKER_00]: So I always believe that we want a comprehensive,
32:44.855 --> 32:45.536
[SPEAKER_00]: salt-type.
32:45.556 --> 32:52.423
[SPEAKER_00]: We want to bring the synergistic effects off these cells together, and this is another study I love.
32:53.565 --> 32:57.509
[SPEAKER_00]: We don't have a whole lot of good treatments of alcoholism.
32:57.649 --> 33:04.977
[SPEAKER_00]: I was a medical director for a few rehab centers in Malibu, and I've seen how difficult it is, and this is a really powerful study.
33:04.997 --> 33:07.420
[SPEAKER_00]: They were looking at these alcoholic rats.
33:07.400 --> 33:12.168
[SPEAKER_00]: and looking at how stem cell infusions can change that drinking behavior.
33:12.489 --> 33:20.663
[SPEAKER_00]: So they were giving them just free alcohol 10% for 73 days and then another 27 days of access to 10% or 20% drink as you wish.
33:21.344 --> 33:23.468
[SPEAKER_00]: And then they give them,
33:23.448 --> 33:26.712
[SPEAKER_00]: They actually injected into the cerebrum.
33:26.732 --> 33:31.998
[SPEAKER_00]: So they injected into the brain of these bone marrow derived MSCs or adipose derived MSCs.
33:32.558 --> 33:37.704
[SPEAKER_00]: And then they were allowed to drink either water or alcohol.
33:38.185 --> 33:42.109
[SPEAKER_00]: And they showed a significant reduction of alcohol intake.
33:42.810 --> 33:45.373
[SPEAKER_00]: And then they showed that.
33:46.374 --> 33:49.658
[SPEAKER_00]: So a single dose MSCs were able to reduce
33:49.638 --> 33:52.542
[SPEAKER_00]: the alcohol intake by 50% for 10 days.
33:52.703 --> 33:53.885
[SPEAKER_00]: So that's pretty remarkable.
33:54.445 --> 33:59.673
[SPEAKER_00]: And the second part of the study is really fun because they're really mimicking the rehab situation there.
33:59.694 --> 34:05.302
[SPEAKER_00]: They let these rats drink and drink and then all of a sudden they deprive them for 14 days.
34:05.322 --> 34:07.526
[SPEAKER_00]: So I was like putting them in rehab for 14 days.
34:07.826 --> 34:14.937
[SPEAKER_00]: So on day four of the deprivation, they give them either stem cells or a control, you know, placebo.
34:14.917 --> 34:19.863
[SPEAKER_00]: So, after 14 days, they let them to free intake alcohol.
34:20.163 --> 34:22.967
[SPEAKER_00]: So, they record how much alcohol they drink in 60 minutes.
34:23.387 --> 34:31.557
[SPEAKER_00]: And they were able to show that MSC-infused rats were able to drink about 80 to 85% less.
34:31.897 --> 34:33.018
[SPEAKER_00]: So, this is remarkable.
34:33.279 --> 34:44.552
[SPEAKER_00]: And their suspicion is that alcoholism is driven by neuronal inflammation by decreasing the inflammation
34:44.532 --> 34:45.373
[SPEAKER_00]: addiction behavior.
34:46.154 --> 34:48.597
[SPEAKER_00]: And the last one I want to talk about is anti aging.
34:48.617 --> 34:53.284
[SPEAKER_00]: So last year I actually did a presentation specifically on anti aging benefits of stem cells.
34:53.624 --> 34:59.052
[SPEAKER_00]: And this is area I'm passionate about because I want to help people to prevent the decline and to continue to be vibrant.
35:00.253 --> 35:02.256
[SPEAKER_00]: So I'm just going to give a few examples.
35:02.616 --> 35:06.542
[SPEAKER_00]: Of course, anti aging when you study life span is very difficult to study in people.
35:06.862 --> 35:09.105
[SPEAKER_00]: So you want to study in animals.
35:09.085 --> 35:10.947
[SPEAKER_00]: So the results has been pretty consistent.
35:11.228 --> 35:27.388
[SPEAKER_00]: We're able to see that the maximum lifespan in the stem cell treated mice were able to be increased by about 30 percent and the survival time were able to be increased by 3.5, a 3.2 fold.
35:27.629 --> 35:34.097
[SPEAKER_00]: So these are older rats when they start giving them stem cells even when they're older is
35:34.077 --> 35:39.164
[SPEAKER_00]: Giving them the remaining time, extending them basically, length of them by three times.
35:39.565 --> 35:44.992
[SPEAKER_00]: So that gives a lot of hope for people who are much older, but you're going to have a lot more time left.
35:45.032 --> 35:49.118
[SPEAKER_00]: And not only longer time left, but it's also better health span.
35:49.158 --> 35:50.020
[SPEAKER_00]: They look a lot better.
35:50.100 --> 35:50.741
[SPEAKER_00]: They're smarter.
35:51.121 --> 35:51.882
[SPEAKER_00]: They're more active.
35:51.922 --> 35:53.945
[SPEAKER_00]: They're just, you know, they're more vibrant.
35:54.446 --> 35:59.693
[SPEAKER_00]: And there's some chimerism, so which means the sum cells did integrate with a new organism.
35:59.994 --> 36:02.397
[SPEAKER_00]: And that's, to me, that's fine.
36:02.377 --> 36:09.172
[SPEAKER_00]: Another example, age rats, so 10 months old, so they just, you know, middle aged, they're aged.
36:09.192 --> 36:17.550
[SPEAKER_00]: And then they were giving them intravenous stem cells, and they, again, showed about, you know, 23 to 31% extension.
36:17.530 --> 36:32.832
[SPEAKER_00]: of their lifespan, and not only lifespan was extended, when they examined their brain and their muscles, the brain neurotrophot factors and the muscle neurotrophot factors both have been restored to a level higher than the younger rats.
36:33.753 --> 36:40.442
[SPEAKER_00]: And when they look at their number of blood vessels, the number of blood vessels were stored to equivalent to the younger rats.
36:40.462 --> 36:43.707
[SPEAKER_00]: So everything was restored to the younger state.
36:44.075 --> 36:48.762
[SPEAKER_00]: Um, so here is actually a human study, looking at 20 patients.
36:48.983 --> 37:01.342
[SPEAKER_00]: I think this is conducted in China, a looking at effect of anti-inflammatory effects and anti-aging effect, just one infusion, and then they measure some markers, and then, you know, at two weeks, three months, they look at how they did.
37:01.623 --> 37:07.973
[SPEAKER_00]: There's improvement in skin, hair, nail growth, energy level, libido, mood, sleep, and pain level.
37:07.953 --> 37:09.495
[SPEAKER_00]: Um, so that's that's it.
37:09.515 --> 37:20.952
[SPEAKER_00]: There's could be a lot more, but, you know, there's only 20 minutes, but I encourage anybody that's interested to take the, you know, American Academy, AICT.org.
37:20.972 --> 37:23.415
[SPEAKER_00]: So the course is on there as a their comprehensive course.
37:23.435 --> 37:30.045
[SPEAKER_00]: You get to take home over 300 articles and then, you know, you get different protocols and, you know, a lot of support from me.
37:30.025 --> 37:37.037
[SPEAKER_00]: Thank you for listening to this episode, hope you enjoy the content, and if so, please rate and follow this podcast.
37:37.057 --> 37:42.908
[SPEAKER_00]: To reach me, you can contact uplift longevity center, and that is uplift with a why.
37:43.168 --> 37:46.915
[SPEAKER_00]: You can also subscribe to my YouTube channel, Joy Kong, MD.
37:47.335 --> 37:48.237
[SPEAKER_00]: See you next time!
